ReCell vitiligo trial hits recruitment goal

Avita Medical (ASX:AVH) has reached its enrolment target for a pilot clinical trial of its ReCell Spray-on Skin in skin pigmentation disorders including vitiligo.

The Netherlands Institute for Pigment Disorders has signed on 10 patients for the initial phase of the study, Avita Medical said.

The randomised, blinded-observer, within-patient controlled study will compare the use of ReCell in combination with laser treatment against laser treatment alone.

The institute’s Dr Albert Wolkerstorfer will be the principal investigator of the trial.

“The data from this controlled trial will provide strong clinical data on the effectiveness of ReCell in the management and treatment of vitiligo and other skin dyspigmentation conditions,” Avita Medical CEO William Dolphin said.

“This study, and other clinical trials underway or starting, are an important part of our overall regulatory and commercial strategy to bring ReCell to the broadest number of patients in need of new treatment options.”

Vitiligo, a condition where patches of the skin lose their pigment, affects an estimated 1.5% of the global population. There is no current medical standard of care for the condition.

ReCell is already used in a variety of burns, plastic, reconstructive and cosmetic surgery procedures. It is approved in Australia, Europe and China but is not yet available in the US.

This month, Avita Medical announced the enrolment of the first patient for a trial of ReCell in venous leg ulcers (VLUs).

Avita Medical (ASX:AVH) shares were trading unchanged at $0.13 as of around 1.30 pm on Thursday.